Crinetics Pharmaceuticals Company Insiders
CRNX Stock | USD 35.10 0.84 2.34% |
Slightly above 88 percent of Crinetics Pharmaceuticals' insiders are activelly selling. The analysis of the overall insider sentiment regarding Crinetics Pharmaceuticals suggests that a very large number of insiders are panicking. Crinetics Pharmaceuticals employs about 437 people. The company is managed by 15 executives with a total tenure of roughly 40 years, averaging almost 2.0 years of service per executive, having 29.13 employees per reported executive.
Scott Struthers CEO CEO, Co-Founder, Director |
Stephen Betz President Co-Founder, Vice President - Biology |
Insider Sentiment 12
Mostly Selling
Selling | Buying |
Latest Trades
2025-03-19 | Dana Pizzuti | Disposed 2515 @ 34.2 | View | ||
2025-02-03 | Dana Pizzuti | Disposed 5000 @ 39.07 | View | ||
2025-01-29 | Gilbert Ray Cisneros, Jr. | Acquired @ 39.38 | |||
2024-11-22 | Jeff E Knight | Disposed 501 @ 56.52 | View | ||
2024-10-03 | Dana Pizzuti | Disposed 14375 @ 54.63 | View | ||
2024-09-26 | Marc Wilson | Disposed 25000 @ 51.11 | View | ||
2024-09-25 | Josh Gottheimer | Acquired @ 50.45 | |||
2024-09-10 | Stephen F Betz | Disposed 1035 @ 51.5 | View | ||
2024-08-26 | Stephen F Betz | Disposed 3000 @ 53.19 | View | ||
2024-07-25 | Stephen F Betz | Disposed 3000 @ 53.43 | View | ||
2024-07-15 | Jeff E Knight | Disposed 27000 @ 55 | View | ||
2024-07-10 | Stephen F Betz | Disposed 3000 @ 48.55 | View | ||
2024-07-05 | James Hassard | Disposed 15000 @ 44.08 | View | ||
2024-07-03 | Dana Pizzuti | Disposed 14375 @ 44.87 | View | ||
2024-06-28 | Marc Wilson | Disposed 32129 @ 43.61 | View | ||
2024-06-26 | Jeff E Knight | Disposed 956 @ 44.38 | View |
Monitoring Crinetics Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Acquired vs Disposed
Filed vs Not Filed
Insider sentiment refers to the collective sentiment or feeling of Crinetics Pharmaceuticals' insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of Crinetics Pharmaceuticals. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe Crinetics Pharmaceuticals' stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.
Crinetics |
Crinetics Pharmaceuticals' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Crinetics Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that Crinetics will maintain a workforce of slightly above 440 employees by April 2025.Crinetics Pharmaceuticals' latest congressional trading
Congressional trading in companies like Crinetics Pharmaceuticals, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Crinetics Pharmaceuticals by those in governmental positions are based on the same information available to the general public.
2024-10-03 | Representative Josh Gottheimer | Acquired Under $15K | Verify |
Crinetics Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.2046) % which means that it has lost $0.2046 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3202) %, meaning that it created substantial loss on money invested by shareholders. Crinetics Pharmaceuticals' management efficiency ratios could be used to measure how well Crinetics Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.22 in 2025. Return On Capital Employed is likely to drop to -0.26 in 2025. At this time, Crinetics Pharmaceuticals' Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 382 M in 2025, whereas Other Assets are likely to drop 1.09 in 2025.Common Stock Shares Outstanding is likely to rise to about 84.8 M in 2025, despite the fact that Net Loss is likely to grow to (140.1 M).
Crinetics Pharmaceuticals Workforce Comparison
Crinetics Pharmaceuticals is rated third in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 3,494. Crinetics Pharmaceuticals retains roughly 437 in number of employees claiming about 13% of equities under Health Care industry.
Crinetics Pharmaceuticals Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Crinetics Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Crinetics Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Crinetics Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2025-03-01 | 1.0769 | 14 | 13 | 980,500 | 75,285 |
2024-12-01 | 0.4 | 2 | 5 | 16,706 | 41,582 |
2024-09-01 | 0.4211 | 8 | 19 | 124,504 | 262,970 |
2024-06-01 | 1.1053 | 21 | 19 | 350,703 | 472,112 |
2024-03-01 | 1.0769 | 28 | 26 | 1,079,750 | 305,275 |
2023-12-01 | 0.4286 | 6 | 14 | 276,583 | 512,166 |
2023-09-01 | 0.25 | 1 | 4 | 10,000 | 60,000 |
2023-06-01 | 2.6667 | 16 | 6 | 189,500 | 113,422 |
2023-03-01 | 1.5556 | 14 | 9 | 955,750 | 27,692 |
2022-12-01 | 0.4286 | 3 | 7 | 253,600 | 29,856 |
2022-09-01 | 0.4286 | 3 | 7 | 8,188 | 26,588 |
2022-06-01 | 2.8 | 14 | 5 | 494,405 | 108,444 |
2022-03-01 | 2.0 | 20 | 10 | 1,150,450 | 54,803 |
2021-12-01 | 0.15 | 3 | 20 | 1,315,337 | 661,810 |
2021-09-01 | 0.5556 | 5 | 9 | 181,046 | 52,092 |
2020-09-01 | 0.5 | 1 | 2 | 25,000 | 35,000 |
2020-06-01 | 0.6364 | 7 | 11 | 1,159,257 | 662,042 |
2020-03-01 | 0.1154 | 3 | 26 | 315,000 | 378,186 |
2019-12-01 | 0.5 | 1 | 2 | 3,500 | 7,000 |
2019-09-01 | 2.0 | 2 | 1 | 35,000 | 10,000 |
2019-06-01 | 2.0 | 6 | 3 | 1,278,305 | 1,465,805 |
2019-03-01 | 0.6 | 9 | 15 | 305,324 | 1,816,958 |
2018-09-01 | 1.2174 | 28 | 23 | 15,491,270 | 15,974,922 |
Crinetics Pharmaceuticals Notable Stakeholders
A Crinetics Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Crinetics Pharmaceuticals often face trade-offs trying to please all of them. Crinetics Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Crinetics Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Scott Struthers | CEO, Co-Founder, Director | Profile | |
Stephen Betz | Co-Founder, Vice President - Biology | Profile | |
Jeff Knight | Chief Officer | Profile | |
James Hassard | Chief Officer | Profile | |
Adriana MBA | Chief Officer | Profile | |
Gayathri Diwakar | Head Relations | Profile | |
Dana MD | Chief Officer | Profile | |
Robert MD | Senior Affairs | Profile | |
Marc Wilson | Chief Officer | Profile | |
Kevin Capps | Head Property | Profile | |
Alan MD | Chief Endocrinologist | Profile | |
Garlan Adams | General Secretary | Profile | |
Chris MBA | Chief Officer | Profile | |
Marc CPA | Chief Officer | Profile | |
Tobin Schilke | Chief Officer | Profile |
About Crinetics Pharmaceuticals Management Performance
The success or failure of an entity such as Crinetics Pharmaceuticals often depends on how effective the management is. Crinetics Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Crinetics management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Crinetics management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.21) | (0.22) | |
Return On Capital Employed | (0.25) | (0.26) | |
Return On Assets | (0.21) | (0.22) | |
Return On Equity | (0.23) | (0.21) |
Please note, the imprecision that can be found in Crinetics Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Crinetics Pharmaceuticals. Check Crinetics Pharmaceuticals' Beneish M Score to see the likelihood of Crinetics Pharmaceuticals' management manipulating its earnings.
Crinetics Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Crinetics Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Crinetics Pharmaceuticals within its industry.Crinetics Pharmaceuticals Manpower Efficiency
Return on Crinetics Pharmaceuticals Manpower
Revenue Per Employee | 2.4K | |
Revenue Per Executive | 69.3K | |
Net Loss Per Employee | 682.9K | |
Net Loss Per Executive | 19.9M | |
Working Capital Per Employee | 3M | |
Working Capital Per Executive | 87.7M |
Additional Tools for Crinetics Stock Analysis
When running Crinetics Pharmaceuticals' price analysis, check to measure Crinetics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crinetics Pharmaceuticals is operating at the current time. Most of Crinetics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Crinetics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crinetics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Crinetics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.